Drugs / JNJ-90301900
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07219212 | Jan 2026 → Jul 2028 expected | head and neck squamous cell carcinoma | Johnson & Johnson Enterprise Innovation Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06667908 | Dec 2024 → Dec 2028 expected | non-small cell lung carcinoma | Johnson & Johnson Enterprise Innovation Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04892173 | Dec 2021 → Jun 2028 expected | squamous cell carcinoma | Johnson & Johnson Enterprise Innovation Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-17 | Nanobiotix | Results Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer nanobiotix.com ↗
Early results suggest that intratumoral/intranodal injection of JNJ-1900 (NBTXR3) is feasible and can be performed safely in patients with stage III unresectable NSCLC |
All press releases naming this drug 1 release
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-90301900 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06667908 ↗ |
| Modality | Other / unclassified | “It is a special kind of nanoparticle that is injected into cancer cells.” PMID 40323213 ↗ May 2025 |
| Route | Other | “JNJ-90301900 (NBTXR3), as an intratumoral/intranodal injection, activated by investigator's choice of RT alone or RT in combination with cetuximab.” NCT04892173 ↗ |